Trial Profile
Rivastigmine in the treatment of Sleep REM Behaviour Disorder (RBD) and Hallucinations in Parkinsonism: a Clinical and Polysomnographic study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2012
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Hallucinations; Parkinsonian disorders; Sleep disorders
- Focus Pharmacodynamics
- 24 Mar 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 30 Jan 2012 Primary endpoint 'REM-sleep' has been met according to results published in Movement Disorders.
- 30 Jan 2012 Results published in Movement Disorders.